C. KentOsborneMD

Oncology • Houston, TX

Breast Cancer, Hematologic Oncology

Director, Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine

Join to view full profile

Dr. Osborne is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Osborne's full profile

Already have an account?

Office
1919 Old Spanish Trl FL 8
Houston, TX 77054
Phone+1 832-957-6500

Fax+1 713-798-1990

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1974 - 1977
Johns Hopkins UniversityResidency, Internal Medicine, 1972 - 1974
University of Missouri-Columbia School of MedicineClass of 1972

Certifications & Licensure

TX State Medical License 1977 - 2025
MD State Medical License 1974 - 1991
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
Top Doctors:SE Texas Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Redbook Magazine: Top Breast Cancer Doctors Castle Connolly, 2001
Join now to see all

Publications & Presentations

PubMed

2 citations
IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer.
Longyong Xu, Fanglue Peng, Qin Luo, Yao Ding, Fei Yuan
Cell. 2024-12-12
4 citations
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer.
Xiaoyong Fu, Resel Pereira, Chia-Chia Liu, Carmine De Angelis, Martin J Shea
Cell Reports. 2023-08-29
4 citations
A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer.
Jamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, Robert Davis, Tao Wang
Clinical Cancer Research. 2023-08-15

Journal Articles

The Oral Selective Oestrogen Receptor Degrader (SERD) AZD9496 Is Comparable to Fulvestrant in Antagonising ER and Circumventing Endocrine Resistance
Rinath Jeselsohn, Mothaffar F Rimawi, C Kent Osborne, Rachel Schiff, Nature

Press Mentions

Postmenopausal Women Who Shed Pounds See Lower Breast Cancer RiskDecember 18th, 2017
Fulvestrant Bests Anastrozole in Advanced Breast CancerDecember 18th, 2014
San Antonio Breast Cancer Symposium: More to Come on 2011 Practice ChangersNovember 28th, 2012